In conclusion, CNOT4 may enhance the efficacy of anti‐PD‐1 immunotherapy and may have potential as a prognostic marker for NSCLC, or as a combinational target with anti‐PD‐1 treatment for patients with NSCLC. Here, CNOT4 is linked to non-small cell lung carcinoma.